Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis

PURPOSE: Compare treatment switching rates and costs among biologic-naive psoriasis patients initiating apremilast or biologics. METHODS: This retrospective claims analysis used IBM MarketScan Commercial and Medicare Supplemental databases to identify patients who initiated apremilast or a biologic...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clinicoecon Outcomes Res
Asıl Yazarlar: Kaplan, David L, Ung, Brian L, Pelletier, Corey, Udeze, Chuka, Khilfeh, Ibrahim, Tian, Marc
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove 2020
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7373411/
https://ncbi.nlm.nih.gov/pubmed/32765022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S251775
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller